Our research shows the transformative effect that alemtuzumab can have for people with MS.
Patients who continue to show disease activity while on their initial therapy are especially difficult to treat.
Now, we have shown that alemtuzumab works where first-line drugs have already failed.
It not only reduces the chances of disability associated with MS but may even result in long-term clinical improvements.
More top news
The PM has promised to end austerity, the chancellor has promised to balance the books by the mid 2020s - the IFS doubts both can be done.
Brussels warned Britain is ‘more likely than ever before’ to crash out of the European Union without a deal.
Figures show the National Cyber Security Centre has handled more than 10 attacks per week in its first two years.